{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:53:31Z","timestamp":1772942011372,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13075-015-0803-2","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T21:48:18Z","timestamp":1444859298000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Continuously elevated serum matrix metalloproteinase-3 for 3\u2009~\u20096\u00a0months predict one-year radiographic progression in rheumatoid arthritis: a prospective cohort study"],"prefix":"10.1186","volume":"17","author":[{"given":"Jian-Da","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiu-Ning","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Qian","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le-Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"key":"803_CR1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205\u201319.","journal-title":"N Engl J Med."},{"key":"803_CR2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492\u2013509.","journal-title":"Ann Rheum Dis."},{"key":"803_CR3","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/ard.2011.154625","volume":"71","author":"S Lillegraven","year":"2012","unstructured":"Lillegraven S, Prince FH, Shadick NA, Bykerk VP, Lu B, Frits ML, et al. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR\/EULAR remission criteria in an observational cohort. Ann Rheum Dis. 2012;71:681\u20136.","journal-title":"Ann Rheum Dis."},{"key":"803_CR4","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1002\/art.30634","volume":"63","author":"D Aletaha","year":"2011","unstructured":"Aletaha D, Smolen JS. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. Arthritis Rheum. 2011;63:3702\u201311.","journal-title":"Arthritis Rheum."},{"key":"803_CR5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1136\/annrheumdis-2013-204986","volume":"74","author":"K Hambardzumyan","year":"2015","unstructured":"Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015;74:1102\u20139.","journal-title":"Ann Rheum Dis."},{"key":"803_CR6","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.3899\/jrheum.131412","volume":"41","author":"IM Markusse","year":"2014","unstructured":"Markusse IM, Dirven L, van den Broek M, Bijkerk C, Han KH, Ronday HK, et al. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatol. 2014;41:2114\u20139.","journal-title":"J Rheumatol."},{"key":"803_CR7","doi-asserted-by":"crossref","first-page":"537324","DOI":"10.1155\/2014\/537324","volume":"2014","author":"D Denarie","year":"2014","unstructured":"Denarie D, Constant E, Thomas T, Marotte H. Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? Mediators Inflamm. 2014;2014:537324.","journal-title":"Mediators Inflamm."},{"key":"803_CR8","first-page":"179284","volume":"2014","author":"JD Ma","year":"2014","unstructured":"Ma JD, Zhou JJ, Zheng DH, Chen LF, Mo YQ, Wei XN, et al. Serum matrix metalloproteinase-3 as a noninvasive biomarker of histological synovitis for diagnosis of rheumatoid arthritis. Mediators Inflamm. 2014;2014:179284.","journal-title":"Mediators Inflamm."},{"key":"803_CR9","first-page":"3301","volume":"8","author":"JD Ma","year":"2013","unstructured":"Ma JD, Ou-Yang X, Zheng DH, Mo YQ, Zou CJ, Zhu LJ, et al. Combined detection of serum matrix metalloproteinase-3 and C-reactive protien in disease activity measurement in female patients with rheumatoid arthritis. Chin J Clinicians (Electronic Edition). 2013;8:3301\u20135.","journal-title":"Chin J Clinicians (Electronic Edition)."},{"key":"803_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324.","journal-title":"Arthritis Rheum."},{"key":"803_CR11","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CR, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138.","journal-title":"Ann Rheum Dis."},{"key":"803_CR12","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64:640\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"Suppl 39","key":"803_CR13","first-page":"S14","volume":"23","author":"B Bruce","year":"2005","unstructured":"Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23 Suppl 39:S14\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"803_CR14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","volume":"59","author":"KG Saag","year":"2008","unstructured":"Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59:762\u201384.","journal-title":"Arthritis Rheum."},{"key":"803_CR15","first-page":"1705","volume":"25","author":"ET Koh","year":"1998","unstructured":"Koh ET, Seow A, Pong LY, Koh WH, Chan L, Howe HS, et al. Cross cultural adaptation and validation of the Chinese Health Assessment Questionnaire for use in rheumatoid arthritis. J Rheumatol. 1998;25:1705\u20138.","journal-title":"J Rheumatol."},{"key":"803_CR16","first-page":"261","volume":"27","author":"D Heijde van der","year":"2000","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000;27:261\u20133.","journal-title":"J Rheumatol."},{"key":"803_CR17","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-202433","volume":"73","author":"T Takeuchi","year":"2014","unstructured":"Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, et al. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Ann Rheum Dis. 2014;73:536\u201343.","journal-title":"Ann Rheum Dis."},{"key":"803_CR18","doi-asserted-by":"crossref","first-page":"R210","DOI":"10.1186\/ar4404","volume":"15","author":"M Meyer","year":"2013","unstructured":"Meyer M, Sellam J, Fellahi S, Kotti S, Bastard JP, Meyer O, et al. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Res Ther. 2013;15:R210.","journal-title":"Arthritis Res Ther."},{"key":"803_CR19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jclinepi.2003.10.014","volume":"57","author":"K Bruynesteyn","year":"2004","unstructured":"Bruynesteyn K, van der Heijde D, Boers M, van der Linden S, Lassere M, van der Vleuten C. The Sharp\/van der Heijde method out-performed the Larsen\/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. J Clin Epidemiol. 2004;57:502\u201312.","journal-title":"J Clin Epidemiol."},{"key":"803_CR20","first-page":"1110","volume-title":"Kelley\u2019s Textbook of Rheumatology","author":"SE Sweeney","year":"2013","unstructured":"Sweeney SE, Edward J, Harris D, Firestein GS. Clinical features of rheumatoid arthritis. In: Firestein GS, Budd RC, Gabriel SE, McInnes IB, O\u2019Dell JR, editors. Kelley\u2019s Textbook of Rheumatology. 9th ed. Philadelphia: Saunders; 2013. p. 1110\u20131111.21.","edition":"9"},{"key":"803_CR21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"JA Singh","year":"2012","unstructured":"Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625\u201339.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"803_CR22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/ard.2008.097683","volume":"69","author":"YP Goekoop-Ruiterman","year":"2010","unstructured":"Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis. 2010;69:65-69.","journal-title":"Ann Rheum Dis."},{"key":"803_CR23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/ard.2010.137695","volume":"70","author":"M Soubrier","year":"2011","unstructured":"Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, et al. Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis. 2011;70:611\u20135.","journal-title":"Ann Rheum Dis."},{"key":"803_CR24","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","volume":"71","author":"LG Schipper","year":"2012","unstructured":"Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, et al. A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis. 2012;71:845\u201350.","journal-title":"Ann Rheum Dis."},{"key":"803_CR25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/annrheumdis-2011-200108","volume":"71","author":"Y Urata","year":"2012","unstructured":"Urata Y, Uesato R, Tanaka D, Nakamura Y, Motomura S. Treating to target matrix metalloproteinase 3 normalisation together with disease activity score below 2.6 yields better effects than each alone in rheumatoid arthritis patients: T-4 Study. Ann Rheum Dis. 2012;71:534\u201340.","journal-title":"Ann Rheum Dis"},{"key":"803_CR26","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/acr.22010","volume":"65","author":"JE Pope","year":"2013","unstructured":"Pope JE, Haraoui B, Rampakakis E, Psaradellis E, Thorne C, Sampalis JS, et al. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. Arthritis Care Res (Hoboken). 2013;65:1401\u20139.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"803_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0009-8981(92)90105-Y","volume":"211","author":"K Obata","year":"1992","unstructured":"Obata K, Iwata K, Okada Y, Kohrin Y, Ohuchi E, Yoshida S, et al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin Chim Acta. 1992;211:59\u201372.","journal-title":"Clin Chim Acta."},{"key":"803_CR28","first-page":"183653","volume":"2013","author":"MM Ally","year":"2013","unstructured":"Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M, Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis. Mediators Inflamm. 2013;2013:183653.","journal-title":"Mediators Inflamm."},{"key":"803_CR29","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1093\/rheumatology\/keu413","volume":"54","author":"V Navarro-Compan","year":"2015","unstructured":"Navarro-Compan V, Gherghe AM, Smolen JS, Aletaha D, Landewe R, van der Heijde D. Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. Rheumatology (Oxford). 2015;54:994\u20131007.","journal-title":"Rheumatology (Oxford)"},{"key":"803_CR30","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1002\/art.22923","volume":"56","author":"S Young-Min","year":"2007","unstructured":"Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, et al. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum. 2007;56:3236\u201347.","journal-title":"Arthritis Rheum."},{"key":"803_CR31","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar3734","volume":"14","author":"M Houseman","year":"2012","unstructured":"Houseman M, Potter C, Marshall N, Lakey R, Cawston T, Griffiths I, et al. Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8\u00a0years follow up. Arthritis Res Ther. 2012;14:R30.","journal-title":"Arthritis Res Ther."},{"key":"803_CR32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejphar.2012.10.030","volume":"698","author":"J Huang","year":"2013","unstructured":"Huang J, Xie B, Li Q, Xie X, Zhu S, Wang M, et al. Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis. Eur J Pharmacol. 2013;698:429\u201334.","journal-title":"Eur J Pharmacol."},{"key":"803_CR33","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/s10165-009-0203-z","volume":"19","author":"K Funahashi","year":"2009","unstructured":"Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol. 2009;19:507\u201312.","journal-title":"Mod Rheumatol."},{"key":"803_CR34","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00296-011-2326-8","volume":"33","author":"K Kanbe","year":"2013","unstructured":"Kanbe K, Chiba J, Nakamura A. Immunohistological analysis of synovium treated with abatacept in rheumatoid arthritis. Rheumatol Int. 2013;33:1883\u20137.","journal-title":"Rheumatol Int."}],"updated-by":[{"DOI":"10.1186\/s13075-015-0837-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T00:00:00Z","timestamp":1446595200000}}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-015-0803-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T17:19:55Z","timestamp":1498238395000},"score":1,"resource":{"primary":{"URL":"http:\/\/arthritis-research.com\/content\/17\/1\/289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["803"],"URL":"https:\/\/doi.org\/10.1186\/s13075-015-0803-2","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13075-015-0837-5","asserted-by":"object"}]},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]},"article-number":"289"}}